ABEO
Abeona Therapeutics Inc. Common Stock
stockNASDAQ
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.36 | 2026-10-14 | +3.56% | 5.309 |
| 1M | 5.67 | 2026-09-21 | -20.37% | 2.727 |
| 3M | 6.53 | 2026-07-21 | -30.86% | 1.231 |
| 6M | 5.38 | 2026-04-21 | -16.08% | 1.369 |
| 1Y | 5.47 | 2025-10-21 | -17.46% | 1.507 |
| 2Y | 6.55 | 2024-10-21 | -31.07% | — |
| 5Y | 22.60 | 2021-10-21 | -80.02% | 0.945 |
Abeona Therapeutics Inc. Common Stock (NASDAQ:ABEO) stock price today is $4.52, and today's volume is 494,625. ABEO is down 1.848% today. The 30 day average volume is 1.45M. ABEO market cap is $258.19M with 57.18M shares outstanding.